Arcellx’s $115 Million Series C Financing

Wilson Sonsini Goodrich & Rosati advised Arcellx on the deal.

Arcellx, a privately held clinical-stage biopharmaceutical company, announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds will support the company’s development of CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 and anticipated to begin a pivotal trial in 2022. In addition, the funding will support initiation of clinical trials evaluating ACLX-001 and ACLX-002, cell therapies derived from Arcellx’s uniquely controllable ARC-SparX platform, in multiple myeloma (MM) and acute myelogenous leukemia (AML), respectively.

The Wilson Sonsini team includes partner Dan Koeppen (Picture), and associates Meghan Burton and Amanda Creedon.

Involved fees earner: Meghan Burton – Wilson Sonsini Goodrich & Rosati; Amanda Creedon – Wilson Sonsini Goodrich & Rosati; Dan Koeppen – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: Arcellx;

Print Friendly, PDF & Email
Martina Bellini

Author: Martina Bellini